Preclinical evaluation of progesterone combined with EDP-M scheme in 2D and 3D models of adrenocortical carcinoma
Open Access
- 10 February 2026
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119090
Abstract
No abstract availableKeywords
Funding Information
- Università degli Studi di Brescia
- Associazione Italiana per la Ricerca sul Cancro (IG27233)
- Associazione Italiana per la Ricerca sul Cancro (IG23009)
This publication has 37 references indexed in Scilit:
- An update on adrenocortical cell lines of human originEndocrine, 2022
- Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinomaESMO Open, 2022
- Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- In vitro antitumor activity of progesterone in human adrenocortical carcinomaEndocrine, 2018
- A reductionist metastasis‐on‐a‐chip platform for in vitro tumor progression modeling and drug screeningBiotechnology and Bioengineering, 2016
- Medroxyprogesterone and tamoxifen augment anti‐proliferative efficacy and reduce mitochondria‐toxicity of epirubicin in FM3A tumor cells in vitroCell Biology International, 2013
- Adrenocortical cell linesMolecular and Cellular Endocrinology, 2004
- Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinomaCancer, 1998
- A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer: A study of the Eastern Cooperative Oncology Group (E2185)Cancer, 1996
- The role of progestins in hormone replacement therapyAmerican Journal of Obstetrics and Gynecology, 1992